
|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Liberated?
Author(s)Wayne Koberstein
Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.
Advertisement
Articles in this issue
almost 25 years ago
Internet DTC - Minding Your P's & Q'salmost 25 years ago
Regulation: Two-Track Planalmost 25 years ago
Policy: Tectonic Shiftalmost 25 years ago
A Matter of Tastealmost 25 years ago
Partnerships: Bargaining Biotechsalmost 25 years ago
Pediatric Mandatealmost 25 years ago
Genentech's Passion for Patientsalmost 25 years ago
Regulation: OK After AllNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
What Governance Resets Should Pharma Companies Take in Response to AI?
3
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
4
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
5




